iOnctura
Latest round
- Series B
Last raised
- Jun 2024
Total raised
- $108M
Investors
- 7
About iOnctura
D., iOnctura SA operates as a provider of small-molecule cancer therapies targeting the tumor-stroma-immune interface in healthcare institutions. The company provides a wide range of oncology therapies, such as PI3Kd inhibitors, autotaxin inhibitors, and TGF-ß pathway inhibitors. These therapies target immune resistance and fibrotic tumors across indications like uveal melanoma, pancreatic cancer, and solid tumors. Additionally, the firm also provides services such as clinical trials and research partnerships to advance oncology drug development.
Who invested in iOnctura
7 investors across 3 rounds
See all investors in iOnctura
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about iOnctura
Who invested in iOnctura?
iOnctura has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has iOnctura raised?
iOnctura has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did iOnctura last raise money?
iOnctura's most recent round on record is a Series B, in Jun 2024.
What does iOnctura do?
iOnctura is a biotechnology company.
Where is iOnctura headquartered?
iOnctura is headquartered in Geneva, Switzerland.
Which VCs invest in companies like iOnctura?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at iOnctura's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like iOnctura? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.